论文部分内容阅读
目的研究探讨乙肝患者血清AFP水平升高的临床表现。方法随机抽取2010年2月~2013年10月本院接诊的89例AFP≥400μg/L的乙肝患者作为研究对象,对其临床资料进行回顾性分析,将AFP升高时间超过2个月的42例患者设为观察组,其余47例患者设为对照组,观察组患者在保守治疗的基础上加用干扰素,观察患者肝脏损害程度、预后以及治疗情况。结果 AFP水平升高与肝脏损害程度多数呈正相关;多数患者AFP接近正常水平或明显降低,少数反复升高者恶化为肝癌;观察组患者33例(78.6%)AFP恢复正常显著优于对照组18(38.3%);观察组患者血清AFP水平显著优于对照组,二者比较差异有统计学意义(P<0.05)。结论经干预,大部分乙肝AFP升高患者可好转或者恢复,仅有少数患者预后不理想。
Objective To study the clinical manifestations of elevated serum AFP level in patients with hepatitis B Methods A total of 89 patients with AFP ≥400 μg / L admitted to our hospital from February 2010 to October 2013 were enrolled in this study. The clinical data of the patients were retrospectively analyzed. The AFP elevated for more than 2 months Forty-two patients were enrolled in the observation group and the remaining 47 patients were assigned as the control group. The patients in the observation group were given interferon on the basis of conservative treatment, and the extent of liver damage, prognosis and treatment were observed. Results The level of AFP was positively correlated with the degree of liver damage. The AFP in most patients was almost normal or significantly decreased, while the number of patients with repeated hyperplasia was worsened to liver cancer. 33 cases (78.6%) in observation group were significantly better than those in control group (38.3%). The level of serum AFP in observation group was significantly better than that in control group, the difference was statistically significant (P <0.05). Conclusion After intervention, the majority of hepatitis B AFP patients can improve or recover, and only a few patients have poor prognosis.